Implications of circulating chromogranin A in prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 41, Issue 4, 2007, Pages 297-301

  Hirano, Daisaku ^a   Minei, Sadatsugu ^a   Sugimoto, Shuji ^a   Yamaguchi, Kenya ^a   Yoshikawa, Tetsuo ^a   Hachiya, Takahiko ^a   Kawata, Nozomu ^a   Yoshida, Toshio ^a   Takahashi, Satoru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Circulating chromogranin A; Neuroendocrine differentiation; Prostate cancer

Indexed keywords

CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX;

EID: 34548442082     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590701303934     Document Type: Article

References (26)

1. Di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-61.
2. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". Pathol Res Pract 1989;185:373-80.
3. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19:91-8.
4. Abrahamsson PA, Wadstrom LB, Alumets J, Falker S, Grimelius L. Peptide hormone and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 1986;181:675-83.
5. Aprikian A, Han K, Guy L, Landry F, Begin LR, Chevalier S. Neuroendocrine differentiation and the bombesin/ gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate Suppl 1998;8:52-61.
6. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996;74:910-6.
7. Di Sant'Agnese PA, de Mesy Jensen K. Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med 1984;108:693-6.
8. Di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: recent findings and new concepts. Cancer (Suppl) 1995;75:1850-9.
9. Di Sant'Agnese PA. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects. Urology 1998;51(5A Suppl):121-4.
10. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999;6:503-19.
11. Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001;12(Suppl 2):159-64.
12. Angelsen A, Syversen U, Syridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997;31:110-7.
13. Deftos LJ, Nakada S, Burton DW, diSant'Agnese PA, Cockett AT, Abrahamsson PA. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48:58-62.
14. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiyama N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-5.
15. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto Y. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-92.
16. Whitmore WF Jr. Natural history and staging of prostate cancer. Urol Clin North Am 1984;11:205-20.
17. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-3.
18. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001;12(Suppl 2):153-7.
19. Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997;157:565-8.
20. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146:358-61.
21. Sciarra A, Di Silverio F. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology 2004;63:523-7.
22. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Lucera R, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003;55:168-79.
23. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000;60:741-8.
24. Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, et al. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Prostate 2004;58:421-8.
25. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590-7.
26. Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M, Pichon MF. Serum chromogranin-A in advanced prostate cancer. BJU Int 2001;88:790-6.